source
- Supreme Court refuses to hear pharma challenges to Medicare price negotiation programThe U.S. Supreme Court declined to review lawsuits filed by several brand‑name drug makers against the Medicare drug price negotiation program, dealing a significant setback to the industry. The c…
- Mentari Therapeutics to go public via reverse merger with InMed, raising $290 million for migraine antibody programsMentari Therapeutics, a spinout of Paragon, announced a reverse merger with InMed Pharmaceuticals that will take the company public under the Mentari name. The deal has received board approval fro…